Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) shares traded up 5.7% on Tuesday . The company traded as high as $45.72 and last traded at $45.58, with a volume of 398,130 shares changing hands. The stock had previously closed at $43.11.

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 target price for the company in a report on Wednesday. BMO Capital Markets reissued a “sell” rating and issued a $36.00 target price on shares of Pacira Pharmaceuticals in a report on Friday, August 5th. Brean Capital reissued a “hold” rating on shares of Pacira Pharmaceuticals in a report on Friday, August 5th. Wedbush reissued an “outperform” rating and issued a $105.00 target price (down from $109.00) on shares of Pacira Pharmaceuticals in a report on Thursday, August 4th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $81.00 target price on shares of Pacira Pharmaceuticals in a report on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Pacira Pharmaceuticals has an average rating of “Buy” and an average target price of $73.64.

The firm’s market capitalization is $1.63 billion. The firm has a 50 day moving average of $37.88 and a 200-day moving average of $49.10.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, August 4th. The company reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.16. The business had revenue of $69.60 million for the quarter, compared to analyst estimates of $67.80 million. The company’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.20 earnings per share. Analysts predict that Pacira Pharmaceuticals Inc. will post $0.42 EPS for the current year.

In related news, Director Mark A. Kronenfeld sold 900 shares of the stock in a transaction on Monday, June 6th. The stock was sold at an average price of $46.95, for a total value of $42,255.00. Following the completion of the transaction, the director now directly owns 2,950 shares of the company’s stock, valued at approximately $138,502.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Kristen Marie Williams sold 600 shares of the stock in a transaction on Monday, June 6th. The shares were sold at an average price of $47.20, for a total value of $28,320.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,900 shares of the company’s stock, valued at $325,680. The disclosure for this sale can be found here.

Other hedge funds recently modified their holdings of the company. California Public Employees Retirement System boosted its stake in shares of Pacira Pharmaceuticals by 182.5% in the fourth quarter. California Public Employees Retirement System now owns 77,400 shares of the company’s stock valued at $5,944,000 after buying an additional 50,000 shares during the last quarter. Stephens Investment Management Group LLC boosted its stake in shares of Pacira Pharmaceuticals by 10.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 540,687 shares of the company’s stock valued at $41,519,000 after buying an additional 49,018 shares during the last quarter. KBC Group NV boosted its stake in shares of Pacira Pharmaceuticals by 2,685.7% in the fourth quarter. KBC Group NV now owns 28,024 shares of the company’s stock valued at $2,152,000 after buying an additional 27,018 shares during the last quarter. Morgan Stanley boosted its stake in shares of Pacira Pharmaceuticals by 28.7% in the fourth quarter. Morgan Stanley now owns 120,614 shares of the company’s stock valued at $9,261,000 after buying an additional 26,865 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of Pacira Pharmaceuticals by 38.1% in the fourth quarter. New York State Common Retirement Fund now owns 57,483 shares of the company’s stock valued at $4,414,000 after buying an additional 15,867 shares during the last quarter.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.